![Yvonne Goh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 30 164 $ in data 31/05/2026
Yvonne Goh worked as a Senior Executive-Finance at Leeden National Oxygen Ltd. from 2010 to 2015.
From 2015 to 2020, Ms. Goh was a Finance Manager at SBI Offshore Ltd. Former jobs include Senior Executive-Finance at Leeden National Oxygen Ltd. and Finance Manager at SBI Offshore Ltd.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 25.781 ( 0,22% ) | 30 164 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CYTOMED THERAPEUTICS LIMITED | Direttore Finanziario/CFO | 01/03/2020 |
| Società | Posizione | Fine |
|---|---|---|
| SBI OFFSHORE LIMITED | Direttore Finanziario/CFO | 12/02/2020 |
Leeden National Oxygen Ltd.
 Leeden National Oxygen Ltd. Wholesale DistributorsDistribution Services Operates as an investment holding company with interest in distribution of industrial equipment, hardware and safety products | Direttore Finanziario/CFO | 02/01/2015 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 3 |
|---|---|
Leeden National Oxygen Ltd.
Leeden National Oxygen Ltd. Wholesale DistributorsDistribution Services Operates as an investment holding company with interest in distribution of industrial equipment, hardware and safety products | Distribution Services |
SBI Offshore Ltd.
 SBI Offshore Ltd. Wholesale DistributorsDistribution Services Operates as a holding company whose subsidiaries provides integrated drilling equipment and engineering solutions | Distribution Services |
CytoMed Therapeutics Ltd.
 CytoMed Therapeutics Ltd. BiotechnologyHealth Technology Operates as a pre-clinical biopharmaceutical company that focuses on harnessing licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
